Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring

References

• Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J. Am. Acad. Dermatol. 63(3), 377–386; quiz 387 (2010).
   PubMedGoogle Scholar
• Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch. Dermatol. 133(6), 735–740 (1997).
   PubMed Web of Science ®Google Scholar
• Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med. J. Aust. 184(1), 6–10 (2006).
   PubMed Web of Science ®Google Scholar
• Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N. Engl. J. Med. 353(21), 2262–2269 (2005).
   PubMed Web of Science ®Google Scholar
• Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N. Engl. J. Med. 344(13), 975–983 (2001).
   PubMed Web of Science ®Google Scholar
• Chen JG, Fleischer AB Jr, Smith ED et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol. Surg. 27(12), 1035–1038 (2001).
   PubMed Web of Science ®Google Scholar
• Argenziano G, Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J. Am. Acad. Dermatol. 48(5), 679–693 (2003).
   PubMed Web of Science ®Google Scholar
• Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 3(3), 159–165 (2002).
   PubMed Web of Science ®Google Scholar
• Micantonio T, Fargnoli MC, Piccolo D, Peris K. Letter: changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod. Dermatol. Surg. 33(11), 1403–1405 (2007).
   Google Scholar
• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 146(Suppl. 61), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• Bradford PT. Skin cancer in skin of color. Dermatol. Nurs. 21(4), 170–177, 206; quiz 178 (2009).
   PubMedGoogle Scholar
• Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 375(9715), 673–685 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang H, Ping XL, Lee PK et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am. J. Pathol. 158(2), 381–385 (2001).
   Google Scholar
• Gailani MR, Bale SJ, Leffell DJ et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69(1), 111–117 (1992).
   PubMed Web of Science ®Google Scholar
• Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum. Mol. Genet. 10(7), 757–762 (2001).
   PubMed Web of Science ®Google Scholar
• Menzies SW, Westerhoff K, Rabinovitz H, Kopf AW, McCarthy WH, Katz B. Surface microscopy of pigmented basal cell carcinoma. Arch. Dermatol. 136(8), 1012–1016 (2000).
   PubMed Web of Science ®Google Scholar
• Altamura D, Menzies SW, Argenziano G et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J. Am. Acad. Dermatol. 62(1), 67–75 (2010).
   PubMed Web of Science ®Google Scholar
• Pan Y, Chamberlain AJ, Bailey M, Chong AH, Haskett M, Kelly JW. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J. Am. Acad. Dermatol. 59(2), 268–274 (2008).
   Google Scholar
• Carducci M, Bozzetti M, Foscolo AM, Betti R. Margin detection using digital dermatoscopy improves the performance of traditional surgical excision of basal cell carcinomas of the head and neck. Dermatol. Surg. 37(2), 280–285 (2011).
   PubMed Web of Science ®Google Scholar
• Giacomel J, Zalaudek I. Dermoscopy of superficial basal cell carcinoma. Dermatol. Surg. 31(12), 1710–1713 (2005).
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Ferrara G, Broganelli P et al. Dermoscopy patterns of fibroepithelioma of Pinkus. Arch. Dermatol. 142(10), 1318–1322 (2006).
   PubMedGoogle Scholar
• Tiodorovic-Zivkovic D, Zalaudek I, Ferrara G et al. Clinical and dermatoscopic findings in Bazex–Dupré–Christol and Gorlin–Goltz syndromes. J. Am. Acad. Dermatol. 63(4), 722–724 (2010).
   Google Scholar
• Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J. Invest. Dermatol. 110(6), 880–884 (1998).
   PubMed Web of Science ®Google Scholar
• McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch. Dermatol. 133(5), 593–596 (1997).
   PubMedGoogle Scholar
• Zalaudek I, Moscarella E, Longo C, de Pace B, Argenziano G. The ‘signature’ pattern of multiple basal cell carcinomas. Arch. Dermatol. 148(9), 1106 (2012).
   Google Scholar
• Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br. J. Dermatol. 159(1), 35–48 (2008).
   PubMed Web of Science ®Google Scholar
• Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/jdv.12031 (2012) (Epub ahead of print).
   Google Scholar
• Peris K, Ferrari A, Fargnoli MC, Piccolo D, Chimenti S. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol. Surg. 31(2), 217–220 (2005).
   PubMedGoogle Scholar
• Lacarrubba F, D’Amico V, Nasca MR, Dinotta F, Micali G. Use of dermatoscopy and videodermatoscopy in therapeutic follow-up: a review. Int. J. Dermatol. 49(8), 866–873 (2010).
   PubMed Web of Science ®Google Scholar
• Quatresooz P, Piérard-Franchimont C, Paquet P, Hubert P, Delvenne P, Piérard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur. J. Dermatol. 18(1), 6–10 (2008).
   PubMed Web of Science ®Google Scholar
• Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br. J. Dermatol. 142(6), 1154–1159 (2000).
   PubMed Web of Science ®Google Scholar
• Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J. Invest. Dermatol. 115(2), 273–277 (2000).
   PubMed Web of Science ®Google Scholar
• Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Investig. Dermatol. Symp. Proc. 1(2), 136–142 (1996).
   PubMedGoogle Scholar
• Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E. [Skin diseases in organ transplant patients]. Hautarzt 53(8), 524–533 (2002).
   PubMed Web of Science ®Google Scholar
• Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 344(8925), 788–789 (1994).
   Google Scholar
• Park WS, Lee HK, Lee JY, Yoo NJ, Kim CS, Kim SH. p53 mutations in solar keratoses. Hum. Pathol. 27(11), 1180–1184 (1996).
   Google Scholar
• Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod. Pathol. 19(Suppl. 2), S88–S92 (2006).
   PubMed Web of Science ®Google Scholar
• Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (‘actinic keratosis’). J. Am. Acad. Dermatol. 42(1 Pt 2), 11–17 (2000).
   PubMed Web of Science ®Google Scholar
• Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 63(8), 1727–1730 (2003).
   PubMed Web of Science ®Google Scholar
• Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br. J. Dermatol. 156(Suppl. 3), 8–12 (2007).
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Giacomel J, Argenziano G et al. Dermoscopy of facial nonpigmented actinic keratosis. Br. J. Dermatol. 155(5), 951–956 (2006).
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Giacomel J, Schmid K et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J. Am. Acad. Dermatol. 66(4), 589–597 (2012).
   PubMed Web of Science ®Google Scholar
• Huerta-Brogeras M, Olmos O, Borbujo J et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch. Dermatol. 148(10), 1159–1164 (2012).
   PubMedGoogle Scholar
• Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int. J. Cancer 46(3), 356–361 (1990).
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 42(1 Pt 2), 23–24 (2000).
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur. J. Dermatol. 18(6), 651–659 (2008).
   PubMed Web of Science ®Google Scholar
• de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the Management of Actinic Keratoses. Br. J. Dermatol. 156(2), 222–230 (2007).
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Kerl H; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the Management of Actinic Keratoses. Eur. J. Dermatol. 16(6), 599–606 (2006).
   PubMed Web of Science ®Google Scholar
• Kaçar N, Sanli B, Zalaudek I, Yildiz N, Ergin S. Dermatoscopy for monitoring treatment of actinic keratosis with imiquimod. Clin. Exp. Dermatol. 37(5), 567–569 (2012).
   Google Scholar
• Lee MM, Wick MM. Bowen’s disease. CA. Cancer J. Clin. 40(4), 237–242 (1990).
   Google Scholar
• Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J. Cutan. Pathol. 33(3), 191–206 (2006).
   PubMed Web of Science ®Google Scholar
• Chute CG, Chuang TY, Bergstralh EJ, Su WP. The subsequent risk of internal cancer with Bowen’s disease. A population-based study. JAMA 266(6), 816–819 (1991).
   Google Scholar
• Kossard S, Rosen R. Cutaneous Bowen’s disease. An analysis of 1001 cases according to age, sex, and site. J. Am. Acad. Dermatol. 27(3), 406–410 (1992).
   PubMed Web of Science ®Google Scholar
• Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum. Toxicol. 8(2), 99–104 (1989).
   PubMedGoogle Scholar
• Shim WH, Park HJ, Kim HS et al. Bowenoid Papulosis of the Vulva and Subsequent Periungual Bowen’s Disease Induced by the Same Mucosal HPVs. Ann. Dermatol. 23(4), 493–496 (2011).
   Google Scholar
• Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen’s disease) in immunocompromised patients. J. Am. Acad. Dermatol. 59(1), 68–71 (2008).
   Google Scholar
• Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen’s disease: 2006 update. Br. J. Dermatol. 156(1), 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Argenziano G, Leinweber B et al. Dermoscopy of Bowen’s disease. Br. J. Dermatol. 150(6), 1112–1116 (2004).
   PubMedGoogle Scholar
• Cameron A, Rosendahl C, Tschandl P, Riedl E, Kittler H. Dermatoscopy of pigmented Bowen’s disease. J. Am. Acad. Dermatol. 62(4), 597–604 (2010).
   Google Scholar
• Hu SC, Chiu HH, Chen GS, Ke CL, Cheng ST. Dermoscopy as a diagnostic and follow-up tool for pigmented Bowen’s disease on acral region. Dermatol. Surg. 34(9), 1248–1253; discussion 1253 (2008).
   Google Scholar
• Kao GF. Carcinoma arising in Bowen’s disease. Arch. Dermatol. 122(10), 1124–1126 (1986).
   PubMedGoogle Scholar
• Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J. Am. Acad. Dermatol. 26(3 Pt 2), 467–484 (1992).
   PubMed Web of Science ®Google Scholar
• de Gruijl FR, Rebel H. Early events in UV carcinogenesis–DNA damage, target cells and mutant p53 foci. Photochem. Photobiol. 84(2), 382–387 (2008).
   PubMed Web of Science ®Google Scholar
• Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest. 1(2), 119–126 (1983).
   PubMed Web of Science ®Google Scholar
• Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 345, e5909 (2012).
   PubMed Web of Science ®Google Scholar
• Jensen P, Hansen S, Møller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40(2 Pt 1), 177–186 (1999).
   PubMed Web of Science ®Google Scholar
• Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 26(1), 1–26 (1992).
   PubMed Web of Science ®Google Scholar
• Epstein E, Epstein NN, Bragg K, Linden G. Metastases from squamous cell carcinomas of the skin. Arch. Dermatol. 97(3), 245–251 (1968).
   PubMedGoogle Scholar
• Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J. Am. Acad. Dermatol. 26(5 Pt 1), 720–726 (1992).
   PubMed Web of Science ®Google Scholar
• Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J. Am. Acad. Dermatol. 40(5 Pt 1), 697–701 (1999).
   Google Scholar
• Cassarino DS, Derienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification – part two. J. Cutan. Pathol. 33(4), 261–279 (2006).
   PubMed Web of Science ®Google Scholar
• Rosendahl C, Cameron A, Argenziano G, Zalaudek I, Tschandl P, Kittler H. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch. Dermatol. 148(12), 1386–1392 (2012).
   Google Scholar
• Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J. Am. Acad. Dermatol. 63(3), 361–74; quiz 375 (2010).
   PubMed Web of Science ®Google Scholar
• Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. Ann. Surg. Oncol. 19(13), 4252–4258 (2012).
   Google Scholar
• Jambusaria-Pahlajani A, Kanetsky PA, Karia PS et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 1–9, doi:10.1001/jamadermatol.2013.2456 (2013) (Epub ahead of print).
   Google Scholar
• Miller SJ. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 1–3, doi:10.1001/jamadermatol.2013.2385. (2013) (Epub ahead of print).
   Google Scholar
• Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J. Am. Acad. Dermatol. 26(6), 976–990 (1992).
   PubMed Web of Science ®Google Scholar
• Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol. Surg. 32(11), 1309–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Brantsch KD, Meisner C, Schönfisch B et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 9(8), 713–720 (2008).
   PubMed Web of Science ®Google Scholar
• Motley R, Kersey P, Lawrence C; British Association of Dermatologists; British Association of Plastic Surgeons. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br. J. Plast. Surg. 56(2), 85–91 (2003).
   PubMedGoogle Scholar
• Rapini RP. Comparison of methods for checking surgical margins. J. Am. Acad. Dermatol. 23(2 Pt 1), 288–294 (1990).
   PubMed Web of Science ®Google Scholar
• Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J. Am. Acad. Dermatol. 24(6 Pt 1), 1002–1004 (1991).
   PubMed Web of Science ®Google Scholar
• Tiodorovic-Zivkovic D, Zalaudek I, Longo C, De Pace B, Albertini G, Argenziano G. Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. Eur. J. Dermatol. 22(4), 579–580 (2012).
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Kostaki D, Piccioni A, Micantonio T, Peris K. Dermoscopy in the diagnosis and management of non-melanoma skin cancers. Eur. J. Dermatol. 22(4), 456–463 (2012).
   Google Scholar
• Micantonio T, Gulia A, Altobelli E et al. Vascular patterns in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 25(3), 358–361 (2011).
   Google Scholar
• Scalvenzi M, Lembo S, Francia MG, Balato A. Dermoscopic patterns of superficial basal cell carcinoma. Int. J. Dermatol. 47(10), 1015–1018 (2008).
   Google Scholar
• Marghoob AA, Cowell L, Kopf AW, Scope A. Observation of chrysalis structures with polarized dermoscopy. Arch. Dermatol. 145(5), 618 (2009).
   PubMed Web of Science ®Google Scholar
• Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas. J. Dermatol. 47(1), 1–12 (2006).
   Google Scholar
• Marchac D, Papadopoulos O, Duport G. Curative and aesthetic results of surgical treatment of 138 basal-cell carcinomas. J. Dermatol. Surg. Oncol. 8(5), 379–387 (1982).
   Google Scholar
• Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br. J. Plast. Surg. 58(6), 795–805 (2005).
   PubMedGoogle Scholar
• Wennberg AM, Larkö O, Stenquist B. Five-year results of Mohs’ micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm. Venereol. 79(5), 370–372 (1999).
   Google Scholar
• Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J. Am. Acad. Dermatol. 53(3), 452–457 (2005).
   PubMedGoogle Scholar
• Smeets NW, Kuijpers DI, Nelemans P et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face–results of a retrospective study and review of the literature. Br. J. Dermatol. 151(1), 141–147 (2004).
   PubMed Web of Science ®Google Scholar
• Kimyai-Asadi A, Goldberg LH, Peterson SR, Silapint S, Jih MH. The incidence of major complications from Mohs micrographic surgery performed in office-based and hospital-based settings. J. Am. Acad. Dermatol. 53(4), 628–634 (2005).
   PubMed Web of Science ®Google Scholar
• Boztepe G, Hohenleutner S, Landthaler M, Hohenleutner U. Munich method of micrographic surgery for basal cell carcinomas: 5-year recurrence rates with life-table analysis. Acta Derm. Venereol. 84(3), 218–222 (2004).
   Google Scholar
• Smeets NW, Krekels GA, Ostertag JU et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 364(9447), 1766–1772 (2004).
   PubMed Web of Science ®Google Scholar
• Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA. Treatment of basal cell carcinoma with curettage alone. J. Am. Acad. Dermatol. 54(6), 1039–1045 (2006).
   PubMed Web of Science ®Google Scholar
• Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J. Dermatol. Surg. Oncol. 17(9), 720–726 (1991).
   PubMedGoogle Scholar
• Bernardeau K, Derancourt C, Cambie M et al. [Cryosurgery of basal cell carcinoma: a study of 358 patients]. Ann. Dermatol. Venereol. 127(2), 175–179 (2000).
   Google Scholar
• Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol. Surg. 30(2 Pt 2), 297–300 (2004).
   PubMed Web of Science ®Google Scholar
• Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a Phase III clinical trial. Br. J. Dermatol. 144(4), 832–840 (2001).
   PubMed Web of Science ®Google Scholar
• Childers BJ, Goldwyn RM, Ramos D, Chaffey J, Harris JR. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast. Reconstr. Surg. 93(6), 1169–1173 (1994).
   Google Scholar
• Zagrodnik B, Kempf W, Seifert B et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 98(12), 2708–2714 (2003).
   PubMed Web of Science ®Google Scholar
• Petit JY, Avril MF, Margulis A et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast. Reconstr. Surg. 105(7), 2544–2551 (2000).
   PubMed Web of Science ®Google Scholar
• Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50(5), 722–733 (2004).
   PubMed Web of Science ®Google Scholar
• Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. 152(5), 939–947 (2005).
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Kamin A, Weide BM et al. A Phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J. Am. Acad. Dermatol. 57(4), 616–621 (2007).
   PubMed Web of Science ®Google Scholar
• Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-amino-laevulinate-based photodynamic therapy alone and with prior curettage. Br. J. Dermatol. 145(3), 467–471 (2001).
   PubMed Web of Science ®Google Scholar
• Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 143(9), 1131–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J. Dtsch. Dermatol. Ges. 5(11), 970–976 (2007).
   PubMedGoogle Scholar
• Cuellar F, Vilalta A, Puig S, Palou J, Salerni G, Malvehy J. New dermoscopic pattern in actinic keratosis and related conditions. Arch. Dermatol. 145(6), 732 (2009).
   Google Scholar
• Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast. Reconstr. Surg. 80(1), 47–54 (1987).
   PubMedGoogle Scholar
• Dinehart SM. The treatment of actinic keratoses. J. Am. Acad. Dermatol. 42(1 Pt 2), 25–28 (2000).
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Radakovic S, Calzavara-Pinton PG et al. A prospective, randomized study comparing photodynamic therapy with Metvix® to cryotherapy in actinic keratoses. J. Eur. Acad. Dermatol. Venereol. 14(2), 235 (2000).
   Google Scholar
• Graham GF. Cryosurgery in the management of cutaneous malignancies. Clin. Dermatol. 19(3), 321–327 (2001).
   Google Scholar
• Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol. Surg. 26(8), 728–732 (2000).
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl. 2), 34–40 (2007).
   PubMed Web of Science ®Google Scholar
• Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er:YAG laser. J. Cutan. Laser Ther. 3(2), 63–66 (2001).
   PubMedGoogle Scholar
• Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch. Dermatol. 131(2), 176–181 (1995).
   PubMed Web of Science ®Google Scholar
• Stone PA. The use of modified phenol for chemical face peeling. Clin. Plast. Surg. 25(1), 21–44 (1998).
   Google Scholar
• Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of ultraviolet- or chemically-induced oxidative stress. Skin Pharmacol. Appl. Skin Physiol. 14(6), 363–372 (2001).
   Google Scholar
• Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J. Am. Acad. Dermatol. 47(2), 258–262 (2002).
   PubMed Web of Science ®Google Scholar
• Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br. J. Dermatol. 146(4), 552–567 (2002).
   PubMed Web of Science ®Google Scholar
• Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J. Am. Acad. Dermatol. 48(2), 227–232 (2003).
   PubMed Web of Science ®Google Scholar
• Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J. Dermatolog. Treat. 14(2), 99–106 (2003).
   PubMedGoogle Scholar
• Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 70(Suppl. 2), 30–36 (2002).
   PubMed Web of Science ®Google Scholar
• Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br. J. Dermatol. 146(1), 94–100 (2002).
   PubMed Web of Science ®Google Scholar
• Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch. Dermatol. 133(10), 1239–1242 (1997).
   PubMed Web of Science ®Google Scholar
• Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int. J. Dermatol. 40(11), 709–713 (2001).
   PubMed Web of Science ®Google Scholar
• Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology (Basel) 205(2), 146–152 (2002).
   Google Scholar
• Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J. Am. Acad. Dermatol. 34(4), 638–644 (1996).
   Google Scholar
• Bernard P, Dupuy A, Brun P et al. Treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists: a prospective medical cost analysis. Ann. Dermatol. Venereol. 134(6), 527–533 (2007).
   Google Scholar
• Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. 140(12), 1542 (2004).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 50(5), 714–721 (2004).
   PubMed Web of Science ®Google Scholar
• Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J. Am. Acad. Dermatol. 62(4), 582–590 (2010).
   PubMed Web of Science ®Google Scholar
• Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J. Am. Acad. Dermatol. 62(4), 573–581 (2010).
   PubMed Web of Science ®Google Scholar
• Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J. Drugs Dermatol. 10(2), 165–170 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson L, Schmieder GJ, Werschler WP et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J. Am. Acad. Dermatol. 60(6), 934–943 (2009).
   PubMed Web of Science ®Google Scholar
• Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, Phase IIa study. Australas. J. Dermatol. 50(1), 16–22 (2009).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010–1019 (2012).
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101–1108 (2011).
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur. J. Dermatol. 22(3), 370–374 (2012).
   PubMed Web of Science ®Google Scholar
• Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm. Venereol. 68(3), 236–239 (1988).
   PubMed Web of Science ®Google Scholar
• Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Treatment options for perianal Bowen’s disease: survery of American Society of Colon and Rectal Surgeons Members. Am. Surg. 66(7), 686–688 (2000).
   PubMedGoogle Scholar
• Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery. J. Am. Acad. Dermatol. 52(6), 997–1002 (2005).
   PubMed Web of Science ®Google Scholar
• Tantikun N. Treatment of Bowen’s disease of the digit with carbon dioxide laser. J. Am. Acad. Dermatol. 43(6), 1080–1083 (2000).
   PubMedGoogle Scholar
• Dave R, Monk B, Mahaffey P. Treatment of Bowen’s disease with carbon dioxide laser. Lasers Surg. Med. 32(5), 335 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed I, Berth-Jones J, Charles-Holmes S, O’Callaghan CJ, Ilchyshyn A. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: a prospective study. Br. J. Dermatol. 143(4), 759–766 (2000).
   PubMed Web of Science ®Google Scholar
• Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br. J. Dermatol. 119(2), 231–240 (1988).
   PubMed Web of Science ®Google Scholar
• Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br. J. Dermatol. 135(5), 766–771 (1996).
   PubMed Web of Science ®Google Scholar
• Blank AA, Schnyder UW. Soft-X-ray therapy in Bowen’s disease and erythroplasia of Queyrat. Dermatologica 171(2), 89–94 (1985).
   Google Scholar
• Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen’s disease: lessons for lesions of the lower extremity. J. Am. Acad. Dermatol. 45(3), 401–404 (2001).
   PubMedGoogle Scholar
• Chung YL, Lee JD, Bang D, Lee JB, Park KB, Lee MG. Treatment of Bowen’s disease with a specially designed radioactive skin patch. Eur. J. Nucl. Med. 27(7), 842–846 (2000).
   PubMedGoogle Scholar
• Patel GK, Goodwin R, Chawla M et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 54(6), 1025–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Prinz BM, Hafner J, Dummer R, Burg G, Bruswanger U, Kempf W. Treatment of Bowen’s disease with imiquimod 5% cream in transplant recipients. Transplantation 77(5), 790–791 (2004).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Germain M, Skelton H. Bowen’s disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol. Surg. 27(2), 143–146 (2001).
   PubMed Web of Science ®Google Scholar
• Welch ML, Grabski WJ, McCollough ML et al. 5-fluorouracil iontophoretic therapy for Bowen’s disease. J. Am. Acad. Dermatol. 36(6 Pt 1), 956–958 (1997).
   PubMed Web of Science ®Google Scholar
• Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br. J. Dermatol. 148(3), 539–543 (2003).
   PubMed Web of Science ®Google Scholar
• Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-fluorouracil. J. Cutan. Med. Surg. 7(2), 101–105 (2003).
   PubMed Web of Science ®Google Scholar
• Varma S, Wilson H, Kurwa HA et al. Bowen’s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br. J. Dermatol. 144(3), 567–574 (2001).
   PubMed Web of Science ®Google Scholar
• Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol. 142(6), 729–735 (2006).
   PubMedGoogle Scholar
• Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br. J. Dermatol. 156(2), 320–328 (2007).
   PubMed Web of Science ®Google Scholar
• de Haas ER, Sterenborg HJ, Neumann HA, Robinson DJ. Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Arch. Dermatol. 143(2), 264–265 (2007).
   PubMedGoogle Scholar